Zacks Investment Research downgraded shares of VICAL INC (VICL) from OUTPERFORM to NEUTRAL on July 23, 2014, with a target price of $1.40.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen cancer immunotherapeutics, in which the expressed protein is an immune system stimulant and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on VICAL INC (VICL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment